Virtual Library

Start Your Search

Lixin Wu



Author of

  • +

    EP1.03 - Biology (ID 193)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Biology
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.03-05 - A Meta-Analysis of Association Between Serum Iron Levels and Lung Cancer Risk (ID 94)

      08:00 - 18:00  |  Author(s): Lixin Wu

      • Abstract

      Background

      Many studies conducted on the relationship between serum iron levels and lung cancer risk had produced inconsistent results. We therefore conducted a meta-analysis to determine whether serum iron levels were lower in lung cancer patients compared to those in controls.

      Method

      A literature survey was conducted by searching the PubMed, WanFang, CNKI, and SinoMed databases for articles published as of Mar 1, 2018. Standard mean differences (SMD) with the corresponding 95% confidence intervals (CI) were executed by Stata 12.0 software.

      Result

      A total of 13 publications involving 1118 lung cancer patients and 832 controls were included in our study. The combined results showed that serum iron levels in lung cancer cases had no significantly lower when compared to those in controls [summary SMD = -0.125, 95%CI= -0.439, 0.189, Z = 0.78, p for Z test= 0.435], with high heterogeneity (I2= 89.9%, P< 0.001) found. In the stratified analysis by geographic locations, consistent results were found for serum iron levels between lung cancer patients and controls both in Asian populations [summary SMD = -0.113, 95%CI= -0.471, 0.245] and European populations [summary SMD = -0.215, 95%CI= -0.835, 0.404].

      Conclusion

      Publication bias was not found when evaluated by Begg’s funnel plot and Egger’s regression asymmetry test.In summary, the current study showed that serum iron levels had no significant association on lung cancer risk.

  • +

    EP1.14 - Targeted Therapy (ID 204)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Targeted Therapy
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.14-33 - Intestinal Metastasis from Primary ROS1-Positive Lung Adenocarcinoma Patients Responding to Crizotinib (ID 105)

      08:00 - 18:00  |  Author(s): Lixin Wu

      • Abstract

      Background

      Small intestinal metastases from primary lung cancer are rare. Such patients have a poor prognosis. Early diagnosis of small intestinal metastases is difficult because of the low incidence of clinically apparent symptoms. The standard treatment for small intestinal metastases has not been established.

      Method

      A 69-year-old Chinese man presented for evaluation of a tumor in the right lower lung and mediastinal lymph node enlargement on clinical examination. The clinical stage was cT2N2M0 (stage IIIA). Histologic examination of the tumor revealed lung adenocarcinoma.

      Result

      He received two chemotherapy regimens. However, the disease progressed. He had bloating after chemotherapy and decreased flatus. An abdominal CT scan showed an intestinal effusion with local intestinal obstruction. Medical treatment was ineffective; hence, he underwent a diagnostic laparoscopy. The pathologic evaluation suggested an intestinal metastatic adenocarcinoma from the primary lung cancer. Based on an real-time PCR assay, the tumor had a ROS1 fusion and responded well to crizotinib. The progression-free survival was 7 months.

      Conclusion

      Physicians must be aware of the possibility of intestinal metastases from primary lung cancer. With an accurate diagnosis and thorough evaluation, patients may benefit from targeted therapy.

  • +

    EP1.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 206)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Treatment in the Real World - Support, Survivorship, Systems Research
    • Presentations: 2
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.16-33 - QT Prolongation in an EGFR 19 Deletion Lung Adenocarcinoma Patient from Icotinib Treatment (ID 92)

      08:00 - 18:00  |  Author(s): Lixin Wu

      • Abstract

      Background

      An increasing number of tyrosine kinase inhibitors (TKIs) are available for the treatment of non-small cell lung cancer (NSCLC). QT prolongation is one of the known, but relatively rare, adverse events of several TKIs (e.g. osimertinib, crizotinib). Screening for QT prolongation in (high risk) patients is advised for these TKIs. When a QT prolongation develops, the physician is challenged with the question whether to (permanently) discontinue the TKI.

      Method

      In this perspective, we report on a patient who developed a QT prolongation during icotinib (a first-generation epidermal growth factor receptor [EGFR]-TKI) treatment.

      Result

      On discontinuation of icotinib, he developed a symptomatic disease flare, not responding to subsequent systemic treatment. The main aim of this perspective is to describe the management of QT prolongation in stage IV EGFR 19 deletion mutation NSCLC patients. We also discuss the ethical question of how to weigh the risk of a disease flare due to therapy cessation against the risk of sudden cardiac death. A family history of sudden death and a prolonged QT interval might indicate a familiar long QT syndrome.

      Conclusion

      We have summarised the current monitoring advice for TKIs used in the treatment of lung cancer and the most common druge TKI interactions to consider and to optimise TKI treatment in EGFR mutation patients.

    • +

      EP1.16-34 - Survival Analysis of Icotinib for Brain Metastases in EGFR Mutated Non-Small Cell Lung Cancer (ID 112)

      08:00 - 18:00  |  Author(s): Lixin Wu

      • Abstract

      Background

      Survival and treatment options are limited for patients with brain metastases arising from non-small cell lung cancer (NSCLC). The aim of this study is to investigate the efficacy and survival analysis icotinib treatment for brain metastasis in non-small cell lung cancer patients with EGFR mutation.

      Method

      We retrospectively reviewed NSCLC patients with brain metastases who were treated with icotinib, and the survival rate was calculated by Kaplan-Meier method and log-rank test was used to compare the survival rates. Univariate and multivariate factors for survival were analyzed by COX proportional hazards regression model.

      Result

      116 cases of rain metastases in EGFR mutated non-small cell lung cancer were female, less than 60 years old and non-smoking patients predominant; COX multivariate analysis found that histologic subtype and EGFR gene subtype were independent prognostic factors for these patients.

      Conclusion

      Icotinib showed promising efficacy in NSCLC patients with brain metastases. PFS and OS was longer in patients with adenocarcinoma than in those with a non-adenocarcinoma subtype. PFSand OS was longer in patients with EGFR common mutations than EGFR uncommon mutations.

  • +

    P2.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 187)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Treatment in the Real World - Support, Survivorship, Systems Research
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.16-39 - The Association Between Dietary Protein Intake and the Risk of Lung Cancer: A Meta-Analysis (ID 200)

      10:15 - 18:15  |  Author(s): Lixin Wu

      • Abstract

      Background

      Dietary protein intake had been explored whether had some effective on lung cancer risk, however, the results were not consistent. This meta-analysis aimed to find exact relationship between them.

      Method

      Databases of PubMed, Embase, and Web of Science were retrieved up to January 1, 2019. Summarized odds ratio (OR) with corresponding 95% confidence intervals (CI) were calculated. Publication bias and sensitivity analysis were assessed.

      Result

      Seven articles with 8 independently studies (4 population-based case-control studies (PBCC) and 4 hospital-based case-control studies (HBCC)) involving 2990 cases and 7142 participants were used in this paper. The overall analysis suggested that dietary protein intake had no significant association on lung cancer risk (Summarized OR= 0.951, 95%CI= 0.798-1.134, I2= 53.0%, P for heterogeneity= 0.037). However, when we explored the association between lung cancer risk and geographic location, we found an inverse association among Asian populations (Summarized OR= 0.880, 95%CI= 0.840-0.922), instead of North American populations or European populations.

      Conclusion

      Findings from this meta-analysis indicated that higher intake of protein may be associated with decreased of lung cancer risk among Asian populations, instead of other populations. As some limitations listed in our study, more studies are warranted to further confirm the association between them.